Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$4.84 -0.4%	$4.37	$2.94 ▼ $10.25	$269.79M	3.04	142,780 shs	870,126 shs
IMUX Immunic	$0.70 -1.5%	$0.91	$0.56 ▼ $2.11	$67.07M	1.48	964,359 shs	747,317 shs
LFCR Lifecore Biomedical	$8.19 -0.5%	$6.87	$3.68 ▼ $8.63	$303.23M	0.65	227,558 shs	946,415 shs
TRDA Entrada Therapeutics	$6.91 -1.6%	$8.03	$6.80 ▼ $21.79	$262.26M	-0.06	133,521 shs	545,179 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	-0.41%	+2.54%	+12.56%	+37.50%	-12.32%
IMUX Immunic	-1.46%	-2.78%	-23.09%	-41.67%	-28.62%
LFCR Lifecore Biomedical	-0.49%	+18.01%	+18.70%	+19.56%	+69.57%
TRDA Entrada Therapeutics	-1.57%	-2.95%	-11.07%	-27.72%	-50.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FHTX Foghorn Therapeutics	1.9727 of 5 stars	3.6	0.0	2.7	1.7	0.6
IMUX Immunic	2.6828 of 5 stars	3.6	1.0	3.1	2.5	0.6
LFCR Lifecore Biomedical	1.5829 of 5 stars	1.3	2.0	3.8	4.2	0.6
TRDA Entrada Therapeutics	3.0346 of 5 stars	3.6	2.0	1.6	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	150.52% Upside
IMUX Immunic	3.25	Buy	$11.60	1,557.14% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	-2.32% Downside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	271.44% Upside

Current Analyst Ratings Breakdown

Latest IMUX, FHTX, TRDA, and LFCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/1/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$22.60M	11.94	N/A	N/A	($0.82) per share	-5.90
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A
LFCR Lifecore Biomedical	$128.26M	2.36	N/A	N/A	$0.37 per share	22.14
TRDA Entrada Therapeutics	$210.78M	1.24	$1.59 per share	4.35	$11.46 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-326.95%	-181.34%	8/6/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-35.90%	-551.09%	-13.89%	8/15/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	$0.81	8.53	N/A	N/A	14.39%	5.84%	4.61%	8/12/2025 (Estimated)

Latest IMUX, FHTX, TRDA, and LFCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
4/3/2025	Q3 2025	LFCR Lifecore Biomedical	-$0.14	-$0.19	-$0.05	-$0.47	$33.23 million	$35.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.16	3.16
IMUX Immunic	N/A	0.74	0.74
LFCR Lifecore Biomedical	66.36	2.71	1.59
TRDA Entrada Therapeutics	N/A	21.88	21.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
IMUX Immunic	51.82%
LFCR Lifecore Biomedical	83.36%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	7.58%
IMUX Immunic	4.60%
LFCR Lifecore Biomedical	32.20%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
IMUX Immunic	70	95.82 million	91.41 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.88 million	Optionable

IMUX, FHTX, TRDA, and LFCR Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Upgraded to "Hold" at Wall Street Zen

June 27 at 12:09 AM | marketbeat.com

Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to Sell

June 14, 2025 | marketbeat.com

Millennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

June 12, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC

June 4, 2025 | marketbeat.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

Entrada Therapeutics to start DMD trial in Q3 2025

May 29, 2025 | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29, 2025 | nasdaq.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025 | globenewswire.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.comP

Entrada Cuts 20% of Workforce, Targeting Research Employees

April 30, 2025 | biospace.comB

Entrada lays off 20% of staff weeks after having FDA hold lifted

April 30, 2025 | fiercebiotech.comF

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

April 29, 2025 | zacks.com

Entrada Therapeutics Receives UK Approval To Start Phase 1/2 Trial Of ENTR-601-45 For DMD

March 26, 2025 | nasdaq.com

Entrada receives authorization in the UK to initiate ELEVATE-45-201 study

March 25, 2025 | markets.businessinsider.com

Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK

March 24, 2025 | msn.com

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

March 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, FHTX, TRDA, and LFCR Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$4.84 -0.02 (-0.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.84 0.00 (0.00%)

As of 06/27/2025 04:34 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Immunic NASDAQ:IMUX

$0.70 -0.01 (-1.46%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.68 -0.02 (-3.00%)

As of 06/27/2025 07:59 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Lifecore Biomedical NASDAQ:LFCR

$8.19 -0.04 (-0.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.20 +0.01 (+0.06%)

As of 06/27/2025 04:34 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Entrada Therapeutics NASDAQ:TRDA

$6.91 -0.11 (-1.57%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.90 -0.02 (-0.22%)

As of 06/27/2025 04:34 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time